GER
MCID: GST092
MIFTS: 65

Gastroesophageal Reflux (GER)

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Gastroesophageal Reflux

MalaCards integrated aliases for Gastroesophageal Reflux:

Name: Gastroesophageal Reflux 57 12 76 29 13 6 44 15
Gastroesophageal Reflux Disease 57 12 37 55 15 73
Gerd 57 12 43
Gerd - Gastro-Esophageal Reflux Disease 12
Gastroesophageal Reflux Disease; Gerd 57
Gastroesophageal Reflux, Pediatric 57
Gastro-Esophageal Reflux 12
Gastresophageal Reflux 12
Acid Reflux 12
Ger 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
gastroesophageal reflux:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 109350
Disease Ontology 12 DOID:8534
ICD10 33 K21 K21.9
ICD9CM 35 530.81
MeSH 44 D005764
NCIt 50 C26781
SNOMED-CT 68 54856001
MedGen 42 C0017168
KEGG 37 H01602
UMLS 73 C0017168

Summaries for Gastroesophageal Reflux

MedlinePlus : 43 Your esophagus is the tube that carries food from your mouth to your stomach. Gastroesophageal reflux disease (GERD) happens when a muscle at the end of your esophagus does not close properly. This allows stomach contents to leak back, or reflux, into the esophagus and irritate it. You may feel a burning in the chest or throat called heartburn. Sometimes, you can taste stomach fluid in the back of the mouth. If you have these symptoms more than twice a week, you may have GERD. You can also have GERD without having heartburn. Your symptoms could include a dry cough, asthma symptoms, or trouble swallowing. Anyone, including infants and children, can have GERD. If not treated, it can lead to more serious health problems. In some cases, you might need medicines or surgery. However, many people can improve their symptoms by Avoiding alcohol and spicy, fatty or acidic foods that trigger heartburn Eating smaller meals Not eating close to bedtime Losing weight if needed Wearing loose-fitting clothes NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Gastroesophageal Reflux, also known as gastroesophageal reflux disease, is related to barrett esophagus and peptic esophagitis, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Gastroesophageal Reflux is CHAT (Choline O-Acetyltransferase), and among its related pathways/superpathways are Peptide ligand-binding receptors and Toll Comparative Pathway. The drugs Abraxane and Actiq have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and kidney, and related phenotypes are gastroesophageal reflux and esophagitis

OMIM : 57 Gastroesophageal reflux (GER) is characterized by the retrograde movement of stomach contents into the esophagus. In its most severe form, GER results in extensive tissue damage caused by acid reflux. In adolescents and adults, and even infrequently in children, chronic GER is associated with the risk of developing Barrett metaplasia (614266), a premalignant lesion of the esophageal mucosa (Hu et al., 2000). In turn, Barrett metaplasia is correlated with the development of adenocarcinoma of the esophagus (see 614266), estimated as the fifth most prevalent neoplasia in the Western world (Lagergren et al., 1999). (109350)

Wikipedia : 76 Gastroesophageal reflux disease (GERD), also known as acid reflux, is a long-term condition where... more...

Related Diseases for Gastroesophageal Reflux

Diseases related to Gastroesophageal Reflux via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 312)
# Related Disease Score Top Affiliating Genes
1 barrett esophagus 32.6 TP53 PTGS2 GAST CDX2
2 peptic esophagitis 32.6 IL1B HRH2 CYP2C19 CXCL8
3 gastroparesis 32.4 MLN GHRL GAST CCK
4 esophagitis 31.8 TRPV1 TP53 PTGS2 IL1B HRH2 CYP2C19
5 dyspepsia 31.4 CCK CXCL8 CYP2C19 GHRL HRH2 PTGS1
6 helicobacter pylori infection 31.1 IL1B GAST CYP2C19 CXCL8
7 sleep apnea 30.9 IL1B GHRL CXCL8
8 irritable bowel syndrome 30.7 TRPV1 PYY MLN CCK
9 duodenal ulcer 30.5 IL1B HRH2 GAST CYP2C19 CXCL8 CCK
10 morbid obesity 30.4 PYY GHRL GCG CCK
11 bile reflux 30.4 PTGS2 CDX2 CCK
12 duodenogastric reflux 30.2 PYY NTS MLN GAST CCK
13 constipation 30.1 PYY NTS MLN GAST CHAT CCK
14 zollinger-ellison syndrome 30.1 NTS HRH2 GAST
15 stomach disease 30.0 GHRL HRH2 IL1B MLN PTGS1 PTGS2
16 gastritis 30.0 PTGS2 IL1B HRH2 GHRL GAST CXCL8
17 atrophic gastritis 30.0 TP53 IL1B GHRL GAST CXCL8 CDX2
18 peptic ulcer disease 30.0 PTGS2 IL1B HRH2 GHRL GAST CYP2C19
19 pylorospasm 30.0 MLN GHRL GAST
20 pharyngitis 29.9 PTGS2 IL1B CXCL8
21 bronchial disease 29.9 TRPV1 IL1B CXCL8
22 dumping syndrome 29.9 PYY NTS GCG
23 bulimia nervosa 29.9 PYY GHRL CCK
24 nervous system disease 29.9 TRPV1 TP53 IL1B CHAT
25 central nervous system disease 29.8 TRPV1 TP53 IL1B CHAT
26 esophagus adenocarcinoma 29.8 TP53 PTGS2 CDX2
27 gastric ulcer 29.8 PTGS2 PTGS1 IL1B HRH2 GAST CYP2C19
28 active peptic ulcer disease 29.7 PTGS2 PTGS1 HRH2
29 body mass index quantitative trait locus 11 29.5 TRPV1 PYY GHRL GCG CCK
30 rheumatic disease 29.5 PTGS2 PTGS1 IL1B
31 myocardial infarction 29.2 PTGS2 PTGS1 IL1B GHRL CYP2C19
32 inflammatory bowel disease 29.0 TRPV1 PTGS2 PTGS1 IL1B CXCL8
33 gastrointestinal system disease 28.8 CCK CXCL8 GAST GCG GHRL IL1B
34 neuropathy, hereditary sensory and autonomic, type i, with cough and gastroesophageal reflux 12.6
35 spastic paraplegia 9a, autosomal dominant 11.7
36 hernia, hiatus 11.6
37 spastic paraplegia 9 11.6
38 chronic laryngitis 11.5
39 sandifer syndrome 11.5
40 chronic hiccups 11.5
41 down syndrome 11.5
42 jackhammer esophagus 11.5
43 neuropathy, hereditary sensory and autonomic, type iia 11.3
44 sudden infant death with dysgenesis of the testes syndrome 11.3
45 mental retardation, autosomal dominant 47 11.3
46 autosomal dominant spastic paraplegia type 9 11.3
47 dihydropyrimidinase deficiency 11.2
48 lubs x-linked mental retardation syndrome 11.2
49 encephalopathy, neonatal severe, due to mecp2 mutations 11.2
50 mental retardation, x-linked 98 11.2

Comorbidity relations with Gastroesophageal Reflux via Phenotypic Disease Network (PDN): (show all 14)


Acute Cystitis Anxiety
Bronchitis Chronic Myocardial Ischemia
Deficiency Anemia Dyskinesia of Esophagus
Esophagitis Heart Disease
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Ischemic Heart Disease
Osteoporosis Peptic Esophagitis

Graphical network of the top 20 diseases related to Gastroesophageal Reflux:



Diseases related to Gastroesophageal Reflux

Symptoms & Phenotypes for Gastroesophageal Reflux

Symptoms via clinical synopsis from OMIM:

57
G I:
gastroesophageal reflux
chronic ulcerating esophagitis

Lab:
columnar epithelium-lined distal esophagus

Oncology:
adenocarcinoma of the esophagus risk about 10%


Clinical features from OMIM:

109350

Human phenotypes related to Gastroesophageal Reflux:

32
# Description HPO Frequency HPO Source Accession
1 gastroesophageal reflux 32 HP:0002020
2 esophagitis 32 HP:0100633
3 barrett esophagus 32 HP:0100580

UMLS symptoms related to Gastroesophageal Reflux:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Gastroesophageal Reflux:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.77 CCK CDX2 CHAT GAST GHRL HRH2
2 digestive/alimentary MP:0005381 9.76 CDX2 CHAT GAST GHRL HRH2 PTGS1
3 adipose tissue MP:0005375 9.73 GHRL NTS PTGS2 PYY TP53 TRPV1
4 neoplasm MP:0002006 9.17 CDX2 GAST IL1B PTGS1 PTGS2 TP53

Drugs & Therapeutics for Gastroesophageal Reflux

FDA approved drugs:

(show top 50) (show all 83)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Abraxane 18 49 PACLITAXEL Celgene October 2012
2
Actiq 18 FENTANYL (citrate) Anesta Corporation November 1998
3
Afinitor 18 49 EVEROLIMUS Novartis March 2009
4
Akynzeo 18 49 NETUPITANT AND PALONOSETRON (hydrochloride) Helsinn October 2014
5
Alimta 18 49 PEMETREXED (also Pemetrexed Disodium) Eli Lilly February 2004
6
Aloxi 18 49 PALONOSETRON (hydrochloride) MGI Pharma, Helsinn Healthcare August 2003
7
Anzemet 18 DOLASETRON MESYLATE Hoechst Marion Roussel February 1998
8
Aredia 18 49 PAMIDRONATE DISODIUM Chiron August 1996
9
Aromasin Tablets 18 49 EXEMESTANE Pharmacia & Upjohn October 21. 1999
10
Arranon 18 49 NELARABINE GlaxoSmithKline October 2005
11
Arzerra 18 49 OFATUMUMAB GlaxoSmithKline October 2009
12
Blincyto 18 49 BLINATUMOMAB Amgen December 2014
13
Doxil 18 49 DOXORUBICIN HYDROCHLORIDE Alza June 1999
14
Ellence 18 49 EPIRUBICIN HYDROCHLORIDE Pharmacia & Upjohn September 1999
15
Emend 18 49 APREPITANT FOSAPREPITANT DIMEGLUMINE Merck March 2003
16
Erbitux 18 49 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
17
Erivedge 18 49 VISMODEGIB Genentech January 2012
18
Erwinaze 18 49 asparaginase Erwinia chrysanthemi Eusa Pharma November of 2011
19
Faslodex 18 49 FULVESTRANT AstraZeneca April 2002
20
Femara 18 49 LETROZOLE Novartis January 2001
21
Fusilev 18 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
22
Gilotrif 18 49 AFATINIB DIMALEATE Boehringer Ingelheim July 2013
23
Gliadel Wafer 18 49 CARMUSTINE Rhone-Poulenc Rorer, Guilford Pharmaceuticals February 1997
24
Inform HER-2/neu breast cancer test 18 Oncor January 1998
25
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
26
Iressa 18 49 GEFITINIB AstraZeneca May 2003
27
Ixempra 18 49 IXABEPILONE Bristol-Myers Squibb October 2007
28
Keytruda 18 49 PEMBROLIZUMAB Merck September 2014
29
Kytril 18 GRANISETRON HYDROCHLORIDE Roche/SmithKline Beecham June 2001/ November 1997
30
Leukine 18 SARGRAMOSTIM Immunex on November 24, 1995/ November 1996
31
Lynparza 18 49 OLAPARIB AstraZeneca December 2014
32
Marqibo 18 49 VINCRISTINE SULFATE Talon Therapeutics August 2012
33
Mekinist 18 49 TRAMETINIB DIMETHYL SULFOXIDE GlaxoSmithKline May of 2013
34
Nolvadex 18 49 TAMOXIFEN CITRATE AstraZeneca October 1998
35
Odomzo 18 49 SONIDEGIB PHOSPHATE Novartis Jul-15
36
Opdivo 18 49 NIVOLUMAB Bristol-Myers Squibb March 2015/ December 2014
37
Photodynamic Therapy (& Photofrin) 18 PORFIMER SODIUM Sanofi-aventis January, 1996
38
Photofrin 18 PORFIMER SODIUM QLT January 1998
39
Picato gel 18 INGENOL MEBUTATE LEO Pharma January 2012
40
Pomalyst 18 49 POMALIDOMIDE Celgene February 2013
41
Sancuso 18 GRANISETRON ProStrakan September 2008
42
Sprycel 18 49 DASATINIB Bristol-Myers Squibb June 2006
43
Stivarga 18 49 REGORAFENIB Bayer/ Bayer HealthCare Pharmaceuticals February 2013/ September 2012
44
Sylatron 18 49 PEGINTERFERON ALFA-2B Merck April 2011
45
Tafinlar 18 49 DABRAFENIB MESYLATE GlaxoSmithKline May 2013
46
Taxol 18 49 PACLITAXEL Bristol-Myers Squibb August 1997
47
Taxotere 18 49 DOCETAXEL Rhone Poulenc Rorer May 1996
48
Temodar 18 49 TEMOZOLOMIDE Schering-Plough August 1999
49
Tykerb 18 49 LAPATINIB DITOSYLATE GlaxoSmithKline March 2007
50
Unituxin 18 49 DINUTUXIMAB United Therapeutics March 2015

Drugs for Gastroesophageal Reflux (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 614)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Calcium polycarbophil Approved Phase 4 126040-58-2
2
Trimebutine Approved Phase 4 39133-31-8
3
Rabeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 117976-89-3 5029
4
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 103577-45-3, 138530-94-6 9578005
5
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 103577-45-3 3883
6
Alginic acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-32-7
7
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 73590-58-6 4594
8
Esomeprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
9
mometasone furoate Approved, Vet_approved Phase 4,Phase 2 83919-23-7
10
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
11
Domperidone Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 57808-66-9 3151
12
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
13
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
14
Fluticasone Approved, Experimental Phase 4,Phase 2,Phase 3,Not Applicable 90566-53-3 62924
15
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6
16
Pantoprazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 102625-70-7 4679
17
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-45-6, 75614-87-8 774
18
leucovorin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 58-05-9 6006 143
19
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 738-70-5 5578
20
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 723-46-6 5329
21
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 94-09-7, 1994-09-7 2337
22 tannic acid Approved Phase 4,Phase 3,Not Applicable
23
Baclofen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1134-47-0 2284
24
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 26787-78-0 33613
25
Clarithromycin Approved Phase 4,Not Applicable 81103-11-9 84029
26
Magnesium hydroxide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1309-42-8
27
Metoclopramide Approved, Investigational Phase 4,Phase 3,Not Applicable 364-62-5 4168
28
Ranitidine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 66357-35-5, 66357-59-3 3001055
29
Ethanol Approved Phase 4,Phase 3,Phase 2 64-17-5 702
30
Pectin Approved, Investigational, Vet_approved Phase 4 9000-69-5 441476
31
Citalopram Approved Phase 4 59729-33-8 2771
32
Nitrofurantoin Approved, Vet_approved Phase 4,Phase 3 67-20-9 5353830
33
Polidocanol Approved Phase 4,Phase 3,Phase 2,Phase 1 9002-92-0
34
Lithium carbonate Approved Phase 4 554-13-2
35
Asenapine Approved Phase 4 65576-45-6, 85650-56-2 3001386
36
Ziprasidone Approved Phase 4 146939-27-7 60854
37
Clozapine Approved Phase 4 5786-21-0 2818
38
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
39
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
40
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
41
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
42
Nortriptyline Approved Phase 4,Phase 3,Phase 2 72-69-5 4543
43
Aluminum hydroxide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 21645-51-2
44 Magnesium trisilicate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 14987-04-3
45
Famotidine Approved Phase 4,Phase 2,Phase 3,Not Applicable 76824-35-6 3325
46
Cimetidine Approved, Investigational Phase 4 51481-61-9 2756
47
Nizatidine Approved Phase 4,Phase 3 76963-41-2 3033637
48
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
49
Verapamil Approved Phase 4 52-53-9 2520
50
Pregabalin Approved, Illicit, Investigational Phase 4,Not Applicable 148553-50-8 5486971

Interventional clinical trials:

(show top 50) (show all 1373)
# Name Status NCT ID Phase Drugs
1 Phase IV Study of the Impact of Dietary Fibers on Symptoms and Esophageal Motility in Patients With Non-erosive GERD Unknown status NCT01882088 Phase 4 Mucofalk
2 Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
3 A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy. Unknown status NCT00237068 Phase 4 Lansoprazole; Solutab
4 Effect of Magnesium Alginate on Gastroesophageal Reflux in Infants. Unknown status NCT02806453 Phase 4
5 Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux Esophagitis Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
6 Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance Unknown status NCT01503476 Phase 4
7 Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy Unknown status NCT01328652 Phase 4 dexlansoprazole
8 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
9 Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances Unknown status NCT02277886 Phase 4 sodium alginate;esomeprazole
10 The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate Unknown status NCT02278081 Phase 4 lansoprazole;placebo
11 Transoral Incisionless Fundoplication (TIF) Versus Sham for Treatment of Gastroesophageal Reflux Disease (GERD) Unknown status NCT01110811 Phase 4
12 Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity Unknown status NCT02140073 Phase 4 omeprazole+domperidone SR;omeprazole
13 LGG for Prevention of Infectious Complications During PPI Treatment in Children Unknown status NCT01782118 Phase 4
14 A Prospective Study Comparing the Success Rate of Injection of (DefluxR) Versus (VantrisR) for VUR in Children Unknown status NCT02271035 Phase 4 Deflux;Vantris
15 Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Unknown status NCT01876836 Phase 4
16 PPI-Rebound-Trial. A Study of the Clinical Relevance of the Acid Rebound Phenomena Unknown status NCT00526006 Phase 4 esomeprazole
17 Gastric Functions & Proton Pump Inhibitor( PPI) Study Unknown status NCT00951431 Phase 4 Esomeprazole;Placebo
18 Clinical Study of Laparoscopic Non Banded Vertical Gastroplasty in Bariatric Surgery Unknown status NCT02050477 Phase 4
19 Impact of the Preservation of the Gastric Antrum in the Technique of Sleeve Gastrectomy for the Treatment of the Morbid Obesity Unknown status NCT01550601 Phase 4
20 Evaluation of the Effectiveness of Antibiotic Prophylaxis in Children With a Previous Urinary Tract Infection Unknown status NCT00156546 Phase 4 antibiotic to reduce the recurrence of infection
21 Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment Unknown status NCT02371252 Phase 4 Generic alendronate
22 Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
23 Study of Long-Term Use of Proton-Pump-Inhibitors in General Practice Unknown status NCT00363701 Phase 4 esomeprazole
24 The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease Completed NCT02505945 Phase 4 Omeprazole
25 Symptom Assessment for Patients With Gastro-esophageal Reflux Disease Receiving Helicobacter Pylori Eradication Not yet recruiting NCT02934152 Phase 4 H pylori eradication
26 Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease Completed NCT02351960 Phase 4 Dexlansoprazole
27 Efficacy of Zinc L-carnosine in Maintaining Remission of Gastroesophageal Reflux Disease Not yet recruiting NCT03467438 Phase 4 Zinc-l-carnosine
28 Role of Mosapride in Patients With Gastroesophageal Reflux Disease Completed NCT00729339 Phase 4 mosapride for the first month and placebo for the 2nd month;placebo for the first and mosapride for the second month
29 An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis Completed NCT01008696 Phase 4 Rabeprazole;Lansoprazole
30 Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US Completed NCT00660660 Phase 4 Esomeprazole;Placebo
31 Methoclopramide for Gastroesophageal Reflux in Premature Infants Recruiting NCT02907632 Phase 4 Metoclopramide;Placebo
32 Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340) Completed NCT00246909 Phase 4 Pantoprazole
33 Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00625495 Phase 4 Esomeprazole;Esomeprazole
34 Omeprazole 20 mg in Patients With Laryngopharyngeal reflux and Comorbid Chronic Rhinosinusitis Completed NCT03086070 Phase 4 Omeprazole 20mg;Placebo oral capsule
35 Comparison of Voice Therapy and Antireflex Therapy in LPR Withdrawn NCT02530879 Phase 4 Omeprazole, Lansoprazole, Esomeprazole, Rantidine
36 A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Completed NCT00734097 Phase 4 Esomeprazole 40 mg
37 Safety and Efficacy of Lansoprazole in Patients With Reflux Disease Completed NCT01135368 Phase 4 Lansoprazole
38 The Study of Eustachian Tube Dysfunction and Laryngopharyngeal Reflux Withdrawn NCT02123498 Phase 4 Omeprazole;Ranitidine;Pantoprazole
39 Omeprazole and Reflux Disease - Improvement of Clinical Outcome by Genotype-adjusted Dosing Terminated NCT00537732 Phase 4 omeprazole;omeprazole
40 Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment? Completed NCT00444145 Phase 4 Prevacid
41 Esomeprazole and Gastric Emptying of Beer Completed NCT00472550 Phase 4 esomeprazole 20 mg
42 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) Completed NCT00628342 Phase 4 Esomeprazole;Esomeprazole;Placebo
43 Safety and Efficacy of Lansoprazole 30mg Twice Daily in Treatment of Laryngitis Associated With Gastroesophageal Reflux Terminated NCT00369265 Phase 4 Lansoprazole
44 A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease Terminated NCT01281553 Phase 4 Placebo;Cisapride
45 Prucalopride Treatment for Refractory Gastro-esophageal Reflux Disease Recruiting NCT03676374 Phase 4 Prucalopride;Placebo Oral Tablet
46 On Demand Treatment of Reflux Disease Completed NCT00184522 Phase 4 Aflurax;esomeprazole
47 Effect of Citalopram on Reflux Episodes in Healthy Volunteers Completed NCT03746691 Phase 4 Citalopram HCl;Placebos
48 An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00629564 Phase 4 Esomeprazole;Esomeprazole
49 A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD) Completed NCT00216489 Phase 4 rabeprazole sodium
50 Sleep Disorders and Gastroesophageal Reflux Disease (GERD) Completed NCT00287391 Phase 4 Rabeprazole

Search NIH Clinical Center for Gastroesophageal Reflux

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: gastroesophageal reflux

Genetic Tests for Gastroesophageal Reflux

Genetic tests related to Gastroesophageal Reflux:

# Genetic test Affiliating Genes
1 Gastroesophageal Reflux 29

Anatomical Context for Gastroesophageal Reflux

MalaCards organs/tissues related to Gastroesophageal Reflux:

41
Testes, Lung, Kidney, Liver, Brain, Bone, Heart

Publications for Gastroesophageal Reflux

Articles related to Gastroesophageal Reflux:

(show top 50) (show all 2481)
# Title Authors Year
1
Lifestyle Modifications in Adults and Older Adults With Chronic Gastroesophageal Reflux Disease (GERD). ( 30507666 )
2019
2
Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease. ( 30466671 )
2019
3
Unique Clinical Features of Los Angeles Grade D Esophagitis Suggest That Factors Other Than Gastroesophageal Reflux Contribute to its Pathogenesis. ( 28644313 )
2019
4
Specific Features of Gastroesophageal Reflux Disease in Patients with Overweight (Basis for Personalized Treatment). ( 29923009 )
2018
5
Gastroesophageal reflux symptoms are not sufficient to guide esophageal function testing in lung transplant candidates. ( 29444329 )
2018
6
Gastroesophageal Reflux Frequency, Severity, Age of Onset, Family History and Acid Suppressive Therapy Predict Barrett Esophagus in a Large Population. ( 29356784 )
2018
7
Management of gastroesophageal reflux disease in adults: a pharmacist's perspective. ( 29892570 )
2018
8
Survey on the Adherence to the 2009 NASPGHAN-ESPGHAN Gastroesophageal Reflux Guidelines by Brazilian Paediatricians. ( 29394212 )
2018
9
Scintigraphic Evaluation of Esophageal Motility and Gastroesophageal Reflux in Patients Presenting with Upper Respiratory Tract Symptoms. ( 29430111 )
2018
10
What Is the Impact of High-Resolution Manometry in the Functional Diagnostic Workup of Gastroesophageal Reflux Disease? ( 29888238 )
2018
11
Analysis of Growth, Nutritional Status and Hospital Visitation Scores Associated with Reflux After Nissen Fundoplication in Neurologically Impaired Children with Gastroesophageal Reflux. ( 29018932 )
2018
12
Prevalence of Gastroesophageal Reflux Disease in Saudi Arabia. ( 29416581 )
2018
13
Diagnosis and Management of Gastroesophageal Reflux in Preterm Infants. ( 29915158 )
2018
14
Chronic Obstructive Pulmonary Disease Exacerbations Are Influenced by Gastroesophageal Reflux Disease. ( 29428028 )
2018
15
The Relationship between Primary Acquired Nasolacrimal Duct Obstruction and Gastroesophageal Reflux. ( 29897254 )
2018
16
Impact of Esophageal Atresia on the Success of Fundoplication for Gastroesophageal Reflux. ( 29628411 )
2018
17
Use of Esophageal pH Monitoring to Minimize Proton-Pump Inhibitor Utilization in Patients with Gastroesophageal Reflux Symptoms. ( 29959725 )
2018
18
Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma - where do we stand? ( 29972731 )